Anti-Cytokine Therapy for Hemodialysis InflammatION
Status:
Completed
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION) is a phase II multi-center study
to evaluate the safety and tolerability of anakinra, an IL-1 receptor antagonist, for
patients treated with maintenance hemodialysis.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Interleukin 1 Receptor Antagonist Protein Pharmaceutical Solutions